SmithKline Consumer Healthcare to market Epitope's OraSure HIV sample collection kit.
This article was originally published in The Gray Sheet
Executive Summary
SMITHKLINE CONSUMER HEALTHCARE TO MARKET EPITOPE'S ORASURE oral specimen collection kit for HIV-1 antibody testing under an agreement in principle announced Feb. 21. The agreement provides the SmithKline OTC drug unit with rights to sell the device in the U.S. and most worldwide markets. The kit, along with an Organon Teknika HIV-1 test for laboratory testing of the collected samples, was approved by FDA on Dec. 23, 1994 "for purchase and distribution only through physicians" ("The Gray Sheet" Jan. 2, p. 1).
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.